Navigation Links
Osteoporosis Therapeutics - Pipeline Assessment and Market Forecasts to 2018
Date:10/25/2011

NEW YORK, Oct. 25, 2011 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Osteoporosis Therapeutics - Pipeline Assessment and Market Forecasts to 2018

http://www.reportlinker.com/p0661232/Osteoporosis-Therapeutics---Pipeline-Assessment-and-Market-Forecasts-to-2018.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Pathology

Osteoporosis Therapeutics - Pipeline Assessment and Market Forecasts to 2018

Summary

GlobalData, the industry analysis specialist, has released its new report, "Osteoporosis Therapeutics - Pipeline Assessment and Market Forecasts to 2018". The report is an essential source of information and analysis on the global osteoporosis therapeutics market. The report identifies the key trends shaping and driving the global osteoporosis therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global osteoporosis therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

GlobalData analysis shows that the global osteoporosis therapeutics market stood at $6.9 billion in 2005 and grew at a Compound Annual Growth Rate (CAGR) of 4.5% to reach $8.5 billion in 2010. GlobalData forecasts that the global osteoporosis therapeutics market will grow
'/>"/>

SOURCE Reportlinker
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related medicine technology :

1. Zosano Pharma, Inc. and Asahi Kasei Pharma Corporation Enter Exclusive Licensing Agreement for a Weekly Transdermal Patch Formulation of Teriboneā„¢ (teriparatide acetate) for Osteoporosis
2. Womens Health Therapeutics, Analysis and Market Forecasts to 2016 - High Unmet Need will Drive the Uptake of Novel Drugs in the Menopause and Osteoporosis Markets
3. Tarsa Therapeutics Presents Positive Efficacy and Safety Data Comparing Its Oral Calcitonin to Nasal Calcitonin and Placebo in Phase III Osteoporosis Treatment Trial
4. Lilly Announces Review of Data on Long-Term Raloxifene Treatment for Postmenopausal Osteoporosis Published in Current Medical Research & Opinion
5. Radius, 3M Drug Delivery Systems Sign Development Agreement for Transdermal Delivery of BA058 for Treatment of Osteoporosis
6. Amgen and UCB Announce Positive Phase 2 Results of AMG 785/CDP7851 in Patients With Postmenopausal Osteoporosis (PMO)
7. Tarsa Therapeutics Reports Positive Top-Line Results From Pivotal Phase III ORACAL Trial of its Oral Calcitonin in Treatment of Postmenopausal Osteoporosis
8. ICAP Ocean Tomo Announces Patents for a New and Safer Method of Treatment of Osteoporosis and Tumor Metastasis Using a Novel Zoledronic Acid Combination
9. Commonly Prescribed Osteoporosis Drug Associated with Very Low Risk of Serious Jaw Disease
10. Tarsa Therapeutics Completes Phase III Trial of its Oral Calcitonin for Treatment of Postmenopausal Osteoporosis and Initiates Phase II Trial in Osteoporosis Prevention
11. $1,700,000 Funding of NeoStems Very Small Embryonic-Like Stem Cells Being Developed to Treat Osteoporosis Recommended by the Department of Defense Peer Reviewed Medical Research Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , Jan. 15, 2014 Massachusetts General ... AMGN ) announced today that they ... and validate new therapeutic targets and develop novel ... disorder that affects millions worldwide. The MGH-Broad-Amgen collaboration ... IBD biology, human genetics, genomic technology, and drug ...
(Date:1/15/2014)...  Humberto C. Antunes,  Galderma  worldwide CEO, will receive ... Journal of Drugs in Dermatology (JDD) at the ... event is January 17-20, 2014, at the Omni Orlando Resort at ... The ODAC is a distinguished event that delivers ... clinical and aesthetic dermatology practitioners in the 21 st ...
(Date:1/15/2014)... , Jan. 15, 2014  Manufacturers, ... and technologies must be able to protect ... (IP). (Logo: http://photos.prnewswire.com/prnh/20130716/CL46586LOGO ... nature of the Medical Device Industry, it ... industry sectors of cases involving IP infringement. ...
Breaking Medicine Technology:Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 2Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 3Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 4Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 2Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 3Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 4Intellectual Property Insurance for Medical-related Products and Services 2
(Date:4/14/2014)... orphaned by HIV/AIDS in South Africa may provide insight ... behavior issues in other areas of the world, which ... that could lead to successful interventions. , A ... United Nations mentions that due to the HIV/AIDS pandemic, ... African, children are at an increased risk for mental ...
(Date:4/14/2014)... A new study shows that moderate to severe ... risk of stroke, cancer and death. , Results of ... to severe obstructive sleep apnea were four times more ... times more likely to have a stroke (HR = ... (HR = 3.4), and 2.5 times more likely to ...
(Date:4/14/2014)... Dallas study involving serious youth offenders, the answer to one ... seven years: "How long do you think you,ll live?", According ... offending over time., Author Dr. Alex Piquero said the study ... of them offend at very high rates and commit more ... much later in life offend much less., "In a lot ...
(Date:4/14/2014)... with symptoms increasing dramatically during some of the most important ... has found. , Depressive symptoms increased on average by 68 ... young men, who were around 25 years old when they ... their children. The results of the study were published April ... is the first to identify when young fathers are at ...
(Date:4/14/2014)... Lower weight babies and babies who aren,t breastfed ... risk of developing chronic inflammation and related health ... study. , "There were good reasons to hypothesize ... inflammation in adulthood," says Thomas McDade (Northwestern University), ... in the Child & Brain Development program. "It ...
Breaking Medicine News(10 mins):Health News:Researchers identify children with emotional behavior difficulties 2Health News:Researchers identify children with emotional behavior difficulties 3Health News:Study links severe sleep apnea to increased risk of stroke, cancer and death 2Health News:UT Dallas study: Youth who fail to envision future commit more crimes 2Health News:Young dads at high risk of depression, too 2Health News:Low birth weight, less breastfeeding create later health risks 2
... Conseco, Inc. (NYSE:,CNO) announced that Todd M. Hacker is ... president and treasurer. He will report to Ed,Bonach, Conseco,s ... Conseco from YRC Worldwide, where he was vice,president and ... From 2005-2006, he was senior vice president, finance and,administration, ...
... MCKINNEY, Texas, Jan. 8 Torchmark Corporation,(NYSE: TMK ... market,closes on Wednesday, February 6, 2008. In conjunction with ... listen to a,conference call that will be broadcast live ... a.m. Eastern. At that time a copy of the,Company,s ...
... HGR ) announced today that it plans to report ... on Monday, February 11,2008., The Company plans to issue ... 31, 2007 on Monday, February 11, 2008, after the,close of ... 9:00,a.m., EST, on Tuesday, February 12, 2008. Those wishing to ...
... LAKES, N.J., Jan. 8 Medco Health,Solutions, Inc. (NYSE: ... Jr. today,reiterated the company,s positive outlook for 2008 at ... The company reiterated its guidance for 2008 GAAP diluted ... assets that,existed when Medco became a publicly traded company, ...
... of developing breast cancer among people who carry the BRCA1 ... January 9/16 issue of JAMA. , BRCA1 and BRCA2 are ... magnitude of the risk of breast cancer in BRCA1 and ... options. The risk of breast cancer in BRCA1 and ...
... likely to undergo heart, liver and kidney transplantation , , TUESDAY, ... and rural areas are less likely to get organ transplants ... study found. , The study of almost 175,000 potential transplant ... percent to 15 percent less likely to be wait-listed and ...
Cached Medicine News:Health News:Torchmark Corporation Announces Fourth Quarter 2007 Earnings Release and Conference Call 2Health News:Hanger Orthopedic Group, Inc. Announces 2007 Year-End Earnings Release Conference Call 2Health News:Medco CEO Reiterates Guidance, Positive Outlook for 2008 2Health News:Breast cancer risk varies significantly among BRCA1 and BRCA2 carriers 2Health News:Rural Residents Get Fewer Organ Transplants: Study 2Health News:Rural Residents Get Fewer Organ Transplants: Study 3
Immuno-turbidimetric assay for Free Protein Sby STA© Analyzers. Suspension of microparticles coated with monoclonal antibodies to Free Protein S....
Colorimetric Assay of Unfractionated and Low Molecular Weight Heparins by STA© Analyzers. Lyophilized, patent-pending chromogenic substate, CBS 52.44 of ~4.2 moles/vial and bovine factor Xa ~1.1...
Substrate Plasma for Factor VII Assay by STA© Analyzers. Freeze-dried human plasma from which factor VII has been removed by selective immuno-adsorption....
Substrate Plasma for Factor IX Assay by STA© Analyzers. Freeze-dried human plasma from which factor IX has been removed by selective immuno-adsorption....
Medicine Products: